AbbVie (ABBV) Interest Coverage Ratio (2012 - 2016)
AbbVie (ABBV) posted quarterly Interest Coverage Ratio of 0.37 for Q2 2016, down 118.75% YoY from 1.96 in Q3 2015, and down 103.47% sequentially from 10.6 in Q1 2016.
AbbVie (ABBV) Interest Coverage Ratio (2012 - 2016) Analysis & Trends
AbbVie has disclosed Interest Coverage Ratio across 5 years of filings, most recently posting 0.37 for Q2 2016.
- In Q2 2016, Interest Coverage Ratio fell 118.75% year-over-year to 0.37; the TTM figure through Mar 2017 stood at 28.54 (up 246.11% YoY), while the FY2015 annual figure was 10.48, up 31.84% from the prior year.
- Interest Coverage Ratio fell to 0.37 in Q2 2016, from 10.6 in the prior quarter.
- Over the last five years, Interest Coverage Ratio for ABBV reached as high as 159.6 in Q3 2012 and fell as low as 2.99 in Q4 2014.
- The 5-year median for Interest Coverage Ratio is 15.45 (2013), against an average of 21.39.
- Annual changes were most pronounced in 2015 — Interest Coverage Ratio surged 440.25% — and 2016, when it tumbled 118.75%.
- A 5-year view of Interest Coverage Ratio shows it stood at 19.37 in 2012, then gained by 7.08% to 20.74 in 2013, then slumped by 114.39% to 2.99 in 2014, then surged by 440.25% to 10.16 in 2015, then sank by 103.62% to 0.37 in 2016.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 0.37, 10.6, and 10.16 for Q2 2016, Q1 2016, and Q4 2015 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 23.39 |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -10.80 |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 4.06 |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 10.78 |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | -0.37 |
| Mar 31, 2016 | 10.60 |
| Dec 31, 2015 | 10.16 |
| Sep 30, 2015 | 9.11 |
| Jun 30, 2015 | 1.96 |
| Mar 31, 2015 | 12.78 |
| Dec 31, 2014 | -2.99 |
| Sep 30, 2014 | 6.49 |
| Jun 30, 2014 | 20.75 |
| Mar 31, 2014 | 19.30 |
| Dec 31, 2013 | 20.74 |
| Sep 30, 2013 | 18.28 |
| Jun 30, 2013 | 18.39 |
| Mar 31, 2013 | 18.13 |
| Dec 31, 2012 | 19.37 |
| Sep 30, 2012 | 159.60 |